Figure S1 Longitudinal observation of the clinical course of patients with high levels of cytomegalovirus (CMV) pp65 antigen (CMV-pp65Ag) (>7.5 cells per 5 × 104 peripheral blood leucocytes) at the initial CMV detection. Of all the CMV-pp65Ag-positive cases, 25 patients showed high levels of CMV-pp65Ag. The CMV-pp65Ag became negative in 12 out of the 22 patients treated with ganciclovir (GCV). However, three out of the 12 patients died within one month. Three out if the four patients, whose CMV-pp65Ag levels remained high in spite of GCV therapy, died within one month. Four patients died within one month after the start of GCV therapy before reevaluation of CMV-pp65Ag. Three patients died before the diagnosis of CMV infection and before GCV therapy could be initiated.

Table S1 Underlying DPLDs and CMV-pp65Ag evaluation

Table S2 Onset of underlying DPLDs

Table S3 Patient Details of CMV-pp65Ag detected and non-detected cases

Table S4 Clinical parameters at the start of immunosuppressive treatment and the interval leading to the onset of CMV infection (univariate analysis)*

Table S5 Clinical parameters at the onset of CMV infection and survival from the CMV infection (univariate analysis)*

resp2263_sm_FigS1.tif7048KSupporting info item
resp2263_sm_TS1-S5.doc141KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.